Norbert Bischofberger, Kronos Bio CEO
January 9, 2023 07:00 AM ESTUpdated 08:07 AM
Deals
R&D

Kro­nos and Genen­tech ink $20M can­cer dis­cov­ery pact

Drew Armstrong

Executive Editor

Kro­nos Bio and Roche’s Genen­tech an­nounced a drug dis­cov­ery deal to hunt for and de­vel­op small mol­e­cule drugs aimed at tran­scrip­tion fac­tors that can dri­ve …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times